Chief Financial Officer · LENZ Therapeutics, Inc. (LENZ)

Alethia Young

FY2022 is the first fiscal year CompBrief holds for Alethia Young as a named executive officer of LENZ Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,835,489

Salary $337,500Stock awards $0Bonus $170,000

2nd of 3 named executive officers at Lenz Therapeutics by FY2022 total.

3 named officers on file for LENZ Therapeutics, FY2022

Alethia Young’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how LENZ Therapeutics’s whole pay program stands against its peers

  • LENZ Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LENZ→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 6, 2023 (DEF 14A).

Free

Get Alethia Young’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Alethia Young compensation by year

LENZ Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as LENZ Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$337,500
Bonus$170,000
Stock awards$0
Option awards$1,212,715
Non-equity incentive$115,274
Pension and deferred compensation$0
All other$151,350
Total$1,835,489

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LENZ Therapeutics, Inc. DEF 14A filed June 6, 2023, accession 0000950170-23-026624, and prior-year filings. Open the filing on EDGAR.

How this page was built: the LENZ Therapeutics, Inc. filed document, accession 0000950170-23-026624. Every figure is read from that document and cited to the page and table it appears in. Filed June 6, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option350,000—$5.23

Per the Outstanding Equity Awards at Fiscal Year-End table in LENZ Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

LENZ Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Josh LehrerPresident, Chief Executive Officer and Director$5,490,535
Alethia Young · this pageChief Financial Officer$1,835,489
Philip GutryChief Business Officer$1,382,033

The full LENZ Therapeutics compensation record

free company brief

This page is one person within LENZ Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LENZ Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Alethia Young's compensation dossier · One-time report. No refunds.